Shilpa Medicare
BSE 530549 · ISIN INE790G01031
6 stories, newest first.
- Shilpa Medicare gained 2% after one of its plants received a USFDA approval or acceptance letter for a key drug
- Shilpa Medicare rose about 4.5% after its partner Unicycive Therapeutics received USFDA acceptance of a resubmitted NDA application for a chronic kidney disease drug
- Viewer asked about entering Shilpa Medicare after a 2.7% decline; analyst said wait for the fall to stabilize before buying
- Nimesh flagged possible buying by a large global sovereign fund in Shilpa Medicare at current levels
- Unit 4 at Jadcherla issued Europe GMP Certification by AGES, Austria
- Promoter Group Releases Pledge Over 30,00,000 Shares (1.5337%) Held With Bajaj Finance
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.